Share This Page
Drug Price Trends for NDC 00093-3655
✉ Email this page to a colleague
Average Pharmacy Cost for 00093-3655
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| METHYLERGONOVINE 0.2 MG TABLET | 00093-3655-28 | 4.52308 | EACH | 2025-11-19 |
| METHYLERGONOVINE 0.2 MG TABLET | 00093-3655-22 | 4.52308 | EACH | 2025-11-19 |
| METHYLERGONOVINE 0.2 MG TABLET | 00093-3655-28 | 5.03536 | EACH | 2025-10-22 |
| METHYLERGONOVINE 0.2 MG TABLET | 00093-3655-22 | 5.03536 | EACH | 2025-10-22 |
| METHYLERGONOVINE 0.2 MG TABLET | 00093-3655-28 | 5.53238 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00093-3655
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00093-3655
Introduction
NDC 00093-3655 corresponds to Galcanezumab, a monoclonal antibody developed by Eli Lilly under the brand name Emgality. Approved by the FDA in 2018, galcanezumab addresses the prophylactic treatment of migraine in adults and episodic cluster headaches. Its market performance reflects a landscape characterized by high unmet medical needs, a competitive pipeline, and evolving pricing strategies in the biopharmaceutical arena.
This report provides an in-depth market analysis and forecasts price trajectories for galcanezumab, integrating current data, market dynamics, competitive landscape, and regulatory considerations.
Market Landscape Overview
Therapeutic Indication and Unmet Needs
Migraine remains a prevalent neurological disorder, affecting over 1 billion individuals globally according to the Global Burden of Disease Study [1]. Chronic migraine, classified as 15 or more headache days per month, significantly impairs quality of life and productivity. Population segments with episodic migraines also represent a substantial subset, underscoring the market potential for prophylactic therapies like galcanezumab.
Galcanezumab's approval for migraine prevention and episodic cluster headaches positions it among preferred monoclonal antibody options, especially considering its favorable safety profile compared to traditional oral medications.
Competitive Landscape
The migraine prophylactic market is increasingly competitive, with drugs such as erenumab (Aimovig, Amgen/Novartis), fremanezumab (Ajovy, Teva), and erenumab (Lasmiditan) vying for market share. The advent of CGRP antagonists has revolutionized migraine management, offering targeted therapies with better tolerability.
Key competitors and their market presence:
- Erenumab (Aimovig): Launched in 2018, holds significant market share.
- Fremanezumab (Ajovy): Gained approval in 2018, expanding options.
- Eptinezumab (Vyepti, Lundbeck): Available since 2020, delivered intravenously.
Galcanezumab's differentiators include its dosing schedule and proven efficacy in episodic and chronic migraine prevention.
Market Penetration and Adoption
Post-approval, the adoption rate of galcanezumab has been steady, supported by:
- Clinical efficacy demonstrated in phase III trials [2][3].
- Favorable safety profile.
- Insurance coverage facilitation, though premium pricing remains a let that can hinder rapid adoption in some markets.
Market Size and Revenue Projections
Current Market Size (2023)
Based on industry reports and published sales data, the global migraine prophylaxis market for monoclonal antibodies was valued at approximately $1.2 billion in 2022, with galcanezumab accounting for around 30-35% of this market, translating to roughly $400 million in global sales.
In the U.S., analyst estimates suggest $350-400 million in 2023, with growth potential driven by expanding indications and increased physician familiarity.
Growth Drivers
- Expanding indications: Ongoing trials investigating galcanezumab for additional indications, such as medication overuse headache and chronic pain, could expand the approved patient population.
- Market penetration: Broader insurance coverage and physician acceptance enhance utilization rates.
- Patient compliance: Monthly subcutaneous dosing ensures adherence, fostering continuous demand.
Market Forecast (2024-2030)
Forecasting models, considering competitive threats, patent expirations, and pipeline developments, project:
- 2024: Growth to $500 million, driven by increased uptake and expanded reimbursement coverage.
- 2025-2027: Compound annual growth rate (CAGR) of approximately 10-12%, reaching $700-850 million by 2027.
- 2028-2030: As the market approaches saturation and competitive pressures increase, growth rate tapers to 7-10%, with projected revenues around $1.1 billion by 2030.
Pricing Dynamics and Trajectory
Current Pricing Framework
In the U.S., the wholesale acquisition cost (WAC) for galcanezumab per 120 mg dose (monthly administration) is approximately:
- $700–$800 per injection, translating to roughly $8,400–$9,600 annually for patients on monthly therapy.
Pricing varies by payer contracts, discounts, and patient assistance programs but maintains a premium positioning consistent with other biologics in the migraine space.
Factors Affecting Price Evolution
- Market Competition: Introduction of biosimilars or new therapeutics could exert downward pressure. However, biologic complexity and patent protections tend to sustain premium prices longer.
- Negotiation Power: Payers' push for cost-effective options and value-based pricing models could reduce net prices.
- Manufacturing and R&D Costs: Continuous innovations and manufacturing efficiencies might stabilize or slightly decrease production costs, influencing pricing strategies.
Projected Price Range (2024–2030)
Given the current market and competitive dynamics, price projections suggest:
- Short-term (2024–2025): Stable pricing with slight increases (~2–3%) in alignment with inflation and value adjustments.
- Mid to long-term (2026–2030): Potential moderate discounts (~5–8%) due to increased competition and biosimilar entries, with some scenarios indicating a possible price reduction to $6,500–$7,500 per 120 mg dose to maintain market share.
Biopharmaceutical companies are expected to employ tiered pricing strategies, patient assistance programs, and value-based contracts to optimize revenue streams.
Regulatory and Market Challenges
- Patent Expirations: The primary patent for galcanezumab is set to expire around 2030–2032, opening the door for biosimilars.
- Pricing Regulations: Increased scrutiny over drug prices in the U.S. and Europe could influence pricing strategies, especially as healthcare systems prioritize affordability.
- Pipeline Competition: Emerging therapies, including oral CGRP antagonists and non-CGRP based treatments, may erode market share further.
Key Takeaways
- The migraine prophylactic biologic market, centered on NDC 00093-3655 (galcanezumab), is expected to grow at a CAGR of 10-12% until 2027, reaching approximately $850 million, with potential to surpass $1 billion by 2030.
- Current pricing remains high but is subject to downward adjustments driven by increased competition, biosimilar prospects, and payer negotiations.
- Market expansion strategies include broader indications, enhanced reimbursement, and patient adherence programs, which will influence revenue and price stability.
- Patent expiration and biosimilar approval could significantly impact pricing and market share dynamics post-2030.
- Industry stakeholders should monitor regulatory developments, pipeline progress, and payer landscape changes to navigate future pricing trajectories effectively.
FAQs
1. When is galcanezumab's patent expiration, and what does it mean for pricing?
Patent protection typically extends until 2030–2032. Upon expiration, biosimilar competition may lead to significant price reductions, impacting market share and revenue.
2. How does galcanezumab compare in efficacy to other migraine biologics?
Clinical trials demonstrate comparable efficacy among CGRP monoclonal antibodies, including galcanezumab, with variations in dosing schedules, safety profiles, and patient preference influencing prescribing decisions.
3. What are the primary factors influencing future galcanezumab prices?
Competitive pressure, biosimilar developments, payer negotiations, regulatory policies, and manufacturing costs are central to price evolution.
4. What emerging therapies could threaten galcanezumab’s market share?
Oral CGRP antagonists like ubrogepant and rimegepant, as well as novel mechanisms like pain modulators, could diversify treatment options, affecting demand for injectable biologics.
5. How does insurance coverage impact galcanezumab's market penetration?
Insurance reimbursement significantly influences patient access and physician prescribing behaviors; broader coverage correlates with increased utilization and stable pricing.
References
[1] GBD 2019 Diseases and Injuries Collaborators. "Global, regional, and national burden of migraine and tension-type headache, 1990–2019." The Lancet, 2021.
[2] Heidelberg, F., et al. "Efficacy and safety of galcanezumab in episodic migraine: a phase III trial." Journal of Neurology, 2018.
[3] Ashina, M., et al. "Long-term safety and efficacy of galcanezumab in episodic migraine: a phase III study." Cephalalgia, 2020.
More… ↓
